KPV

Overview

KPV (lysine-proline-valine) is a tripeptide corresponding to the C-terminal three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH) — the same parent hormone that Melanotan I/II and PT-141 are derived from or related to, though KPV's activity profile is notably distinct from those compounds.

Proposed Mechanism of Action

Despite being derived from alpha-MSH, KPV's anti-inflammatory effect is reported to be independent of the melanocortin receptors alpha-MSH normally activates. Instead, the cited research (and related work referenced in our source search) points to PepT1, a peptide transporter normally expressed in the small intestine and upregulated in the colon during inflammatory bowel disease, as the relevant uptake pathway — with KPV then inhibiting NF-κB and MAP kinase inflammatory signaling once inside the cell.

Research Context

The cited study tested orally delivered KPV in two standard mouse models of colitis (DSS-induced and TNBS-induced, two different chemical methods of triggering intestinal inflammation) and found reduced disease severity in both. The PepT1-mediated uptake mechanism is notable because it's specifically relevant to intestinal tissue where PepT1 is expressed — a plausible explanation for why oral delivery worked in this context, unlike most peptides on this site where oral bioavailability is a barrier.

Limitations of the Current Evidence

• The evidence here is limited to mouse colitis models — there is no human clinical trial data in the citation we verified for this profile.
• The PepT1-dependent mechanism is specifically tied to intestinal tissue; it does not, by itself, support broader anti-inflammatory claims for KPV in other tissues or via other administration routes (e.g., systemic injection) without separate supporting evidence.